10th August 2023
Botswana Medicines Regulatory Authority (BoMRA) and Medicines Control Authority of Zimbabwe Strengthen Cooperation Through MoU Renewal
Zimbabwe, Harare: The Botswana Medicines Regulatory Authority, (BoMRA) has renewed its Memorandum of Understanding with the Medicines Control Authority of Zimbabwe, (MCAZ). This renewal strengthens a long-standing partnership between the two nations in the critical area of medicine and medical device regulation.
The renewed MOU focuses on several key areas of collaboration such as: Exchange of Information and Expertise: Both organizations share knowledge on Quality Management Systems, including ISO standards for laboratories and good manufacturing practices for pharmaceuticals. Capacity Building: The agreement facilitates regulatory excellence and professional development through system audits, training, and capacity building exercises. Mutual Support: both authorities will assist each other in strengthening their regulatory processes, benefiting from each other’s experiences and best practices.
It’s worth noting that MCAZ brings significant expertise to this partnership. In 2014, it was designated a Regional Centre of Regulatory Excellence under the African Medicines Regulatory Harmonization initiative. MCAZ offers specialized knowledge in areas such as Evaluation and Registration of medicines, Pharmacovigilance and Clinical trials, and Laboratory testing. MCAZ further achieved Maturity Level 3 as assessed against the World Health Organisation Global Benchmarking tool. BoMRA aspires to achieve Maturity Level 3 which assures that the regulators functions are carried out in alignment with the best practices and having MCAZ as a partner will support BoMRA’s efforts to do so, said BoMRA CEO, Dr. Seima Dijeng.
The agreement includes provisions for confidentiality, ensuring that sensitive information shared between the authorities is protected. This collaboration is expected to enhance the efficiency of medicine registration processes, improve the quality of regulatory decisions, and ultimately ensure better access to safe, high-quality medicines and medical devices for the people of Botswana and Zimbabwe.
The renewal of this MOU reflects a shared commitment to public health and regulatory excellence in our region. It’s a significant step towards harmonizing and strengthening our regulatory systems, which will benefit not just Botswana and Zimbabwe, but potentially the wider Southern African Development Community, concluded the BoMRA CEO.
–ENDS–
For more information, please contact Public Relations: info@bomra.co.bw and or pr@bomra.co.bw TEL: 373 17 27 / 3731728.
NOTES TO THE EDITOR
About BoMRA
BoMRA was established through the Medicines and Related Substances Act to ensure that all human and veterinary medicines, medical devices, cosmetics and related substances conform to the set standards of quality, safety and efficacy.
Medicine regulation in Botswana continues to evolve and as such it is upon the Authority to ensure that it executes its mandate of delivering quality and transparent market authorization services, with the aim of reducing incidents of substandard and falsified medicines and related substances and creating awareness and improved trust to the general public, stakeholders and the health industry in medicines and related substances regulatory systems in Botswana.
About MCAZ
Medicines Control Authority of Zimbabwe (MCAZ) is a statutory body established by an Act of Parliament, The Medicines and Allied Substances Control Act (MASCA) [Chapter 15.03]. MCAZ is a successor of the Drugs Control Council (DCC) and the Zimbabwe Regional Drug Control Laboratory (ZRDCL). DCC was established by an Act of Parliament in 1969: Drugs and Allied Substances Control Act [Chapter 15.03] following which ZRDCL became operational in 1989. MCAZ is responsible for protecting public and animal health by ensuring that accessible medicines and allied substances and medical devices are safe, effective and of good quality through enforcement and adherence to standards by manufacturers and distributors. The mandate of MCAZ is to protect public health ensuring that medicines and medical devices on the market are safe, effective, and of good quality.